Form 4: Amgen Executive Murdo Gordon Reports Stock Transaction

Murdo Gordon, EVP at Amgen, reports disposition of 800 common stock shares to cover tax obligations.

Summary

• On April 30, 2025, Murdo Gordon, EVP at Amgen, reported a transaction involving Amgen's common stock.
• Gordon disposed of 800 shares of common stock at a price of $288.56.
• This transaction resulted in Gordon owning 47,586 shares of Amgen common stock following the reported transaction.
• The disposition of shares was to cover tax obligations.
• The reported shares include 675 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock transaction. It doesn't convey any particularly positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track executive sentiment and potential alignment with company performance.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like Amgen.
• Similar filings are made by executives at comparable companies such as Johnson & Johnson, Pfizer, and Merck, providing insights into their individual investment decisions.
• The number of shares traded and the reasons for the transactions (e.g., tax obligations, diversification) are typical considerations when analyzing these filings.

Stakeholder Impact

• The transaction itself is unlikely to have a significant impact on stakeholders.
• However, transparency in insider transactions is important for maintaining investor confidence.

Key Dates

Keywords

Amgen, Murdo Gordon, stock transaction, Form 4, beneficial ownership, common stock, EVP, insider trading